P&U Predicts Fourth Quarter Launch For "Approvable" Antidepressant Vestra
Executive Summary
Pharmacia & Upjohn and co-promotion partner Janssen expect a fourth quarter launch for the antidepressant Vestra (reboxetine), following FDA "approvable" designation July 29.
You may also be interested in...
Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth
Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.
Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth
Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.
Pharmacia & Upjohn Discussing Mirapex Sudden Sleep Onset With FDA
FDA and Pharmacia & Upjohn are discussing possible labeling changes to the Parkinson's therapy Mirapex (pramipexole) to reflect reports of sudden sleep onset in patients.